Partnership By Biotech Firm Could Be Big News For The Commercialization Of Its Innovative ADHD Drug Candidate

Shane Schaffer, Chairman & CEO of Cingulate CING, and Tim Moore, Senior VP of Biotech of Indegene, were recently guests on Benzinga’s All Access.

Cingulate is a biotechnology company that is developing drugs for a range of underserved conditions. The company has developed a proprietary technology called Precision Timed Release™ (PTR™). The technology allows a single pill to contain multiple doses of a drug, allowing for the relief of the pill burden many people with chronic conditions suffer.

The company has partnered with Indegene, ​​a life sciences commercialization company, to help them commercialize their drug candidate, CTx-1301, a novel ADHD treatment currently in clinical trials.

Watch the full interview here:

Featured photo by Christina Victoria Craft on Unsplash.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.